Crispr Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Crispr Therapeutics AG
CRSP Stock  USD 51.31  1.35  2.70%   
Analyzing historical trends in various income statement and balance sheet accounts from Crispr Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Crispr Therapeutics' valuation are summarized below:
Gross Profit
-430.7 M
Market Capitalization
4.8 B
Enterprise Value Revenue
96.5595
Revenue
38.3 M
Earnings Share
(5.19)
There are currently one hundred twenty fundamental signals for Crispr Therapeutics AG that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Crispr Therapeutics' prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 02/03/2026, Market Cap is likely to drop to about 2.3 B. In addition to that, Enterprise Value is likely to drop to about 2 B

Crispr Therapeutics Total Revenue

38.24 Million

Check Crispr Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crispr Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.3 M, Interest Expense of 56.6 M or Selling General Administrative of 63.7 M, as well as many indicators such as Price To Sales Ratio of 81.11, Dividend Yield of 0.0 or PTB Ratio of 1.62. Crispr financial statements analysis is a perfect complement when working with Crispr Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Crispr Stock
Check out the analysis of Crispr Therapeutics Correlation against competitors.

Crispr Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.4 B2.6 B1 B
Slightly volatile
Other Current Liabilities38.5 M59.2 M28.9 M
Slightly volatile
Total Current Liabilities66.5 M100.9 M49.5 M
Slightly volatile
Other Liabilities15.6 M16.5 M26.8 M
Very volatile
Accounts Payable12.3 M16.9 M9 M
Slightly volatile
Cash510.4 M343 M350.6 M
Slightly volatile
Non Current Assets Total368.2 M350.6 M137.4 M
Slightly volatile
Non Currrent Assets Other33 M31.5 M10.6 M
Slightly volatile
Other Assets19.7 M18.7 M8.6 M
Slightly volatile
Cash And Short Term Investments1.2 B2.2 B879.3 M
Slightly volatile
Net Receivables25.7 M28.8 M19 M
Slightly volatile
Common Stock Total Equity1.6 M2.8 M1.4 M
Slightly volatile
Common Stock Shares Outstanding60.3 M97 M51.6 M
Slightly volatile
Liabilities And Stockholders Equity1.4 B2.6 B1 B
Slightly volatile
Non Current Liabilities Total148.6 M255.5 M111.2 M
Slightly volatile
Other Current Assets13.9 M9.6 M9.5 M
Slightly volatile
Total Liabilities215.7 M356.4 M162.6 M
Slightly volatile
Short and Long Term Debt42 M44.1 M38.8 M
Slightly volatile
Total Current Assets1.2 B2.2 B908.6 M
Slightly volatile
Short Term Debt21.6 M15.6 M28.6 M
Slightly volatile
Intangible Assets13.7 K14.4 K276.6 K
Slightly volatile
Common Stock1.8 M3.1 M1.4 M
Slightly volatile
Short and Long Term Debt Total170.3 M257.2 M109.4 M
Slightly volatile
Property Plant And Equipment Net335.1 M319.2 M123.7 M
Slightly volatile
Long Term Debt Total30.7 M34.5 M37.7 M
Slightly volatile
Capital Surpluse3.3 B3.1 B1.3 B
Slightly volatile
Property Plant And Equipment Gross422.4 M402.3 M121.6 M
Slightly volatile
Property Plant Equipment197.6 M188.2 M70.3 M
Slightly volatile
Current Deferred Revenue3.3 M3.5 M40.6 M
Slightly volatile
Additional Paid In Capital330.2 M358.8 M306.1 M
Slightly volatile
Deferred Long Term Liabilities9.4 M9.9 M46.8 M
Slightly volatile
Non Current Liabilities Other3.8 M4 M19.8 M
Pretty Stable
Net Invested Capital1.6 B2.2 B962.4 M
Slightly volatile
Net Working Capital1.5 B2.1 B951 M
Slightly volatile
Capital Stock2.5 M3.1 M2 M
Slightly volatile
Capital Lease Obligations191.6 M257.2 M115.7 M
Slightly volatile

Crispr Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization23.3 M22.1 M8.7 M
Slightly volatile
Selling General Administrative63.7 M83.9 M47.4 M
Slightly volatile
Other Operating Expenses327.9 M576.8 M247.7 M
Slightly volatile
Research Development224.9 M368.8 M167.6 M
Slightly volatile
Cost Of Revenue114.1 M126.8 M81.6 M
Slightly volatile
Total Operating Expenses265.9 M450 M200.1 M
Slightly volatile
Interest Income9 M4.9 M5.8 M
Pretty Stable
Reconciled Depreciation14 M22.1 M9.4 M
Slightly volatile

Crispr Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings29.7 M31.5 M35.6 M
Slightly volatile
Stock Based Compensation54.7 M99.6 M41.4 M
Slightly volatile
Begin Period Cash Flow486.3 M461.2 M341.9 M
Slightly volatile
Other Cashflows From Financing Activities32.1 M36 M24.1 M
Slightly volatile
Depreciation23.3 M22.1 M8.7 M
Slightly volatile
Capital Expenditures2.1 M2.2 M10.6 M
Slightly volatile
Total Cash From Financing Activities273.5 M381.8 M200.6 M
Slightly volatile
End Period Cash Flow517 M356.2 M355.7 M
Slightly volatile
Issuance Of Capital Stock257.4 M270.6 M308 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio81.1185.381.9 K
Very volatile
Days Sales Outstanding223235581
Very volatile
Stock Based Compensation To Revenue2.112.2325.1185
Pretty Stable
Capex To Depreciation0.110.09874.203
Slightly volatile
Payables Turnover17.098.6213.255
Very volatile
Sales General And Administrative To Revenue1.781.8841.6749
Pretty Stable
Research And Ddevelopement To Revenue7.838.25103
Pretty Stable
Capex To Revenue0.04640.04898.2829
Pretty Stable
Cash Per Share13.6920.3113.0793
Slightly volatile
Days Payables Outstanding35.343.8345.1887
Pretty Stable
Intangibles To Total Assets0.00.00.0984
Slightly volatile
Current Ratio12.7319.8612.3147
Slightly volatile
Receivables Turnover1.21.26352
Pretty Stable
Capex Per Share0.01930.02030.169
Pretty Stable
Revenue Per Share0.350.371.4548
Slightly volatile
Interest Debt Per Share1.562.391.6514
Slightly volatile
Debt To Assets0.110.09980.1348
Slightly volatile
Graham Number32.5253.5135.4032
Slightly volatile
Operating Cycle223235581
Very volatile
Days Of Payables Outstanding35.343.8345.1887
Pretty Stable
Ebt Per Ebit1.030.890.9623
Pretty Stable
Long Term Debt To Capitalization3.323.734.0759
Slightly volatile
Total Debt To Capitalization0.110.121.5171
Slightly volatile
Quick Ratio12.7319.8612.3147
Slightly volatile
Net Income Per E B T0.810.910.985
Slightly volatile
Cash Ratio3.713.916.9326
Pretty Stable
Days Of Sales Outstanding223235581
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.111.171.0171
Slightly volatile
Fixed Asset Turnover0.140.150.7201
Pretty Stable
Debt Ratio0.110.09980.1348
Slightly volatile
Price Sales Ratio81.1185.381.9 K
Very volatile
Asset Turnover0.01330.0140.0585
Pretty Stable

Crispr Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.3 B3 B2.3 B
Slightly volatile

Crispr Fundamental Market Drivers

Forward Price Earnings23.3645
Cash And Short Term Investments1.9 B

Crispr Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Crispr Therapeutics Financial Statements

Crispr Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Crispr Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Crispr Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Crispr Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue3.5 M3.3 M
Total Revenue40.2 M38.2 M
Cost Of Revenue126.8 M114.1 M
Stock Based Compensation To Revenue 2.23  2.11 
Sales General And Administrative To Revenue 1.88  1.78 
Research And Ddevelopement To Revenue 8.25  7.83 
Capex To Revenue 0.05  0.05 
Revenue Per Share 0.37  0.35 
Ebit Per Revenue(15.33)(16.10)

Pair Trading with Crispr Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Crispr Stock

  0.41GILD Gilead Sciences Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Crispr Stock Analysis

When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY